Skip to main content
Livermore
Livermore
US stocksTW
ZHEN

Standard Life Aberdeen plc

SEC CIK
0001716774
Latest filing
Nov 6, 2026

The latest 13F from Standard Life Aberdeen plc covers Q3 2026 (filed Nov 6, 2026): 996 long positions worth $63.5B. The top 10 holdings make up 40.1% of the portfolio, and the largest is Apple Inc. (AAPL) at 8.6%. Livermore has 27 filings on Form 13F from this institution, going back to Q1 2021.

What changed in Q3 2026

Full comparison

Share counts compared with Q2 2026: how many positions were new, added to, reduced or sold out, and the biggest buys and sells. Dollar amounts are estimated at the quarter-end prices implied by the filing.

New
132
Est. +$1.49B
Added
394
Est. +$18.0B
Reduced
454
Est. −$20.4B
Sold out
70
Est. −$511.7M

Top 5 holdings

Share of this quarter's portfolio value

  1. AAPLApple Inc.
    8.6%$5.48BHistory
  2. MUMicron Technology Inc
    5.6%$3.57BHistory
  3. NUENucor Corp
    5.4%$3.42BHistory
  4. AMZNAmazon Com Inc
    5.0%$3.19BHistory
  5. GOOGLAlphabet Inc.
    4.1%$2.60BHistory

Share of portfolio

Top 5 holdings and the other 991 positions, by share of portfolio value

  1. AAPL8.6%
  2. MU5.6%
  3. NUE5.4%
  4. AMZN5.0%
  5. GOOGL4.1%
  6. Other 991 positions71.2%

Biggest buys

New and added positions, by estimated amount bought

  1. NUENucor Corp
    +$3.36BAddedHistory
  2. MUMicron Technology Inc
    +$3.16BAddedHistory
  3. TERTeradyne, Inc
    +$1.59BAddedHistory
  4. VMCVulcan Materials CO
    +$373.1MAddedHistory
  5. MELIMercadolibre Inc
    +$338.4MAddedHistory

Largest weight increases

New and added positions, by percentage points of the portfolio gained

  1. NUENucor Corp
    +5.31 pp0.1% → 5.4%History
  2. MUMicron Technology Inc
    +4.29 pp1.3% → 5.6%History
  3. TERTeradyne, Inc
    +2.48 pp0.1% → 2.6%History
  4. AMZNAmazon Com Inc
    +1.02 pp4.0% → 5.0%History
  5. AMDAdvanced Micro Devices Inc
    +0.69 pp1.2% → 1.9%History

Biggest sells

Reduced and sold-out positions, by estimated amount sold

  1. NVDANVIDIA Corp
    −$4.65BReducedHistory
  2. VIVTelefonica Brasil S.A.
    −$1.15BReducedHistory
  3. PFEPfizer Inc
    −$1.05BReducedHistory
  4. MSFTMicrosoft Corp
    −$992.8MReducedHistory
  5. MDLZMondelez International, Inc.
    −$975.6MReducedHistory

Largest weight decreases

Reduced and sold-out positions, by percentage points of the portfolio lost

  1. NVDANVIDIA Corp
    −5.46 pp5.6% → 0.2%History
  2. MSFTMicrosoft Corp
    −4.67 pp4.7% → <0.1%History
  3. TSLATesla, Inc.
    −3.01 pp3.0% → <0.1%History
  4. METAMeta Platforms, Inc.
    −1.33 pp1.4% → 0.1%History
  5. MRKMerck & Co., Inc.
    −0.71 pp0.8% → 0.1%History

Metrics

13F metrics for Q3 2026, computed only from the numbers in the filings. Definitions below.

Portfolio value
$63.5B
−$7.69B (−10.8%) vs. prior quarter
Positions
996
+62 vs. prior quarter
Top 10 concentration
40.1%
Top 10 as share of value
Turnover
28.9%
Q3 2026, one quarter
Average holding period
20.8 quarters
Weighted by value

How these are calculated

  • Portfolio value: the market value of all long positions in the 13F, as reported at quarter end, excluding options.
  • Top 10 concentration: the combined value of the 10 largest positions as a share of portfolio value.
  • Turnover: the smaller of this quarter's estimated purchases and estimated sales, divided by the average of this and last quarter's portfolio value. Estimates multiply the change in shares by the quarter-end price implied by the filing (market value divided by shares); new positions use this quarter's value and sold-out positions last quarter's. Only positions reported in shares count, and it is not calculated when the previous quarter was not filed.
  • Average holding period: how many consecutive quarters each current position has been held (including this one; a quarter without the position or without a filing starts the count over), weighted by this quarter's value. Counting starts with the first 13F in Livermore (Q1 2021), so positions held before then are understated.

13F filings by quarter

23 quarters, going back to Q1 2021. Bars show each quarter's 13F portfolio value; quarters without a filing are left blank.

Peak $71.2B (Q2 2026)

Q1 2021: $44.0BQ2 2021: $45.7BQ3 2021: $44.4BQ4 2021: $45.5BQ1 2022: $39.1BQ2 2022: $31.8BQ3 2022: $33.6BQ4 2022: $36.8BQ1 2023: $40.0BQ2 2023: $43.0BQ3 2023: $39.2BQ4 2023: $46.1BQ1 2024: $51.0BQ2 2024: $52.2BQ3 2024: $54.5BQ4 2024: $53.3BQ1 2025: $51.3BQ2 2025: $58.8BQ3 2025: $63.2BQ4 2025: $64.6BQ1 2026: $61.9BQ2 2026: $71.2BQ3 2026: $63.5B
Q1 2021Q3 2026
13F filings of Standard Life Aberdeen plc by quarter
QuarterFiledPositionsValueTop 3 holdingsChangesFiling
Q3 2026Nov 6, 2026996$63.5BAAPLMUNUEvs. Q2 2026SEC
Q2 2026Jul 31, 2026934$71.2BAAPLNVDAMSFTvs. Q1 2026SEC
Q1 2026Apr 29, 2026931$61.9BAAPLNVDAMSFTvs. Q4 2025SEC
Q4 2025Jan 16, 2026936$64.6BAAPLMSFTNVDAvs. Q3 2025SEC
Q3 2025Nov 7, 2025952$63.2BMSFTAAPLNVDAvs. Q2 2025SEC
Q2 2025Jul 24, 2025951$58.8BMSFTAAPLNVDAvs. Q1 2025SEC
Q1 2025May 13, 2025942$51.3BAAPLMSFTNVDAvs. Q4 2024SEC
Q4 2024Jan 24, 2025931$53.3BMSFTAAPLNVDAvs. Q3 2024SEC
Q3 2024Oct 25, 2024915$54.5BAAPLMSFTNVDAvs. Q2 2024SEC
Q2 2024Aug 9, 2024946$52.2BMSFTAAPLNVDAvs. Q1 2024SEC
Q1 2024May 9, 2024947$51.0BMSFTAAPLNVDAvs. Q4 2023SEC
Q4 2023Jan 31, 2024960$46.1BMSFTAAPLAMZNvs. Q3 2023SEC
Q3 2023Nov 7, 2023888$39.2BMSFTAAPLAMZNvs. Q2 2023SEC
Q2 2023Jun 20, 2024Amended917$43.0BMSFTAAPLAMZNvs. Q1 2023SEC
Q1 2023Jun 20, 2024Amended913$40.0BMSFTAAPLAMZNvs. Q4 2022SEC
Q4 2022Jun 20, 2024Amended915$36.8BMSFTAAPLAMZNvs. Q3 2022SEC
Q3 2022Nov 10, 2022927$33.6BMSFTAAPLAMZNvs. Q2 2022SEC
Q2 2022Aug 5, 2022950$31.8BMSFTAAPLAMZNvs. Q1 2022SEC
Q1 2022May 4, 2022977$39.1BMSFTAAPLAMZNvs. Q4 2021SEC
Q4 2021Feb 10, 2022Amended1,045$45.5BMSFTAAPLAMZNvs. Q3 2021SEC
Q3 2021Nov 15, 20211,043$44.4BMSFTAAPLAMZNvs. Q2 2021SEC
Q2 2021Aug 10, 20211,012$45.7BMSFTAAPLAMZNvs. Q1 2021SEC
Q1 2021May 6, 2021988$44.0BMSFTAAPLAMZN–SEC

13D and 13G filings

Companies where Standard Life Aberdeen plc reports owning 5% or more on Schedule 13D or 13G, and its latest filings.

Current stakes of 5% or more

8 companies, largest stake first.

Companies where Standard Life Aberdeen plc owns 5% or more
CompanyLatest formStakeChangeFirst filedLatest filingFiling
ELOXEloxx Pharmaceuticals, Inc.13G9.91%400.0K sharesNewJul 27, 20261 filingJul 27, 2026SEC
CDXSCodexis, Inc.13G/A9.86%10.8M shares+2.41 ppfrom 7.45%Jul 30, 20255 filingsOct 30, 2026SEC
DTILPrecision Biosciences Inc13G8.88%2.14M sharesNewJan 27, 20261 filingJan 27, 2026SEC
IMUXImmunic, Inc.13G/A7.99%1.09M shares+1.94 ppfrom 6.05%Jul 31, 20254 filingsNov 2, 2026SEC
NSPRInspireMD, Inc.13G/A7.49%3.17M shares+1.54 ppfrom 5.95%Nov 7, 20252 filingsFeb 2, 2026SEC
SERASera Prognostics, Inc.13G/A7.21%2.75M shares+1.14 ppfrom 6.07%Aug 5, 20252 filingsJul 15, 2026SEC
EQEquillium, Inc.13G/A7.03%4.46M shares+1.73 ppfrom 5.30%May 7, 20262 filingsNov 4, 2026SEC
PRQRProQR Therapeutics N.V.13G6.33%8.93M sharesNewJul 29, 20261 filingJul 29, 2026SEC

Latest filings

40 filings on file made by Standard Life Aberdeen plc or listing it as a reporting person; the latest 20 are shown.

Schedule 13D and 13G filings by Standard Life Aberdeen plc
CompanyFiled (ET)FormStakeChangeEvent dateFiling
EQEquillium, Inc.Nov 4, 20268:17 AM ET13G/A7.03%4.46M shares+1.73 ppfrom 5.30%Sep 30, 2026SEC
IMUXImmunic, Inc.Nov 2, 20268:47 AM ET13G/A7.99%1.09M shares+1.94 ppfrom 6.05%Sep 30, 2026SEC
CDXSCodexis, Inc.Oct 30, 202612:38 PM ET13G/A9.86%10.8M shares+2.41 ppfrom 7.45%Sep 30, 2026SEC
FRNMFreenome, Inc.Oct 29, 202611:40 AM ET13G/A0.61%656.7K shares−5.88 ppfrom 6.49%Below 5%Sep 30, 2026SEC
CRBPCorbus Pharmaceuticals Holdings, Inc.Oct 29, 202611:03 AM ET13G/A0.00%0 shares−7.53 ppfrom 7.53%Below 5%Sep 16, 2026SEC
TECXTectonic Therapeutic, Inc.Oct 29, 202610:57 AM ET13G/A2.48%484.9K shares−3.62 ppfrom 6.10%Below 5%Sep 30, 2026SEC
PRQRProQR Therapeutics N.V.Jul 29, 20269:48 AM ET13G6.33%8.93M sharesNewJun 30, 2026SEC
ELOXEloxx Pharmaceuticals, Inc.Jul 27, 20267:56 AM ET13G9.91%400.0K sharesNewJun 30, 2026SEC
QUREuniQure N.V.Jul 20, 20269:37 AM ET13G/A4.52%2.85M shares−3.97 ppfrom 8.49%Below 5%Jun 30, 2026SEC
CDXSCodexis, Inc.Jul 20, 20267:08 AM ET13G/A7.45%6.77M shares−1.37 ppfrom 8.82%Jun 30, 2026SEC
IMUXImmunic, Inc.Jul 16, 20266:15 AM ET13G/A6.05%824.4K shares−0.80 ppfrom 6.85%Jun 30, 2026SEC
SERASera Prognostics, Inc.Jul 15, 202610:27 AM ET13G/A7.21%2.75M shares+1.14 ppfrom 6.07%Jun 30, 2026SEC
EQEquillium, Inc.May 7, 202611:09 AM ET13G5.30%3.35M sharesNewApr 1, 2026SEC
QUREuniQure N.V.Apr 30, 20268:21 AM ET13G/A8.49%5.31M shares+2.58 ppfrom 5.91%Apr 1, 2026SEC
QNRXQuoin Pharmaceuticals Ltd.Apr 29, 20266:41 AM ET13G/A4.16%75.0K shares−4.78 ppfrom 8.94%Below 5%Apr 1, 2026SEC
FRNMFreenome, Inc.Apr 28, 20269:38 AM ET13G6.49%578.6K sharesNewApr 1, 2026SEC
NSPRInspireMD, Inc.Feb 2, 202610:35 AM ET13G/A7.49%3.17M shares+1.54 ppfrom 5.95%Dec 31, 2025SEC
IMUXImmunic, Inc.Feb 2, 202610:31 AM ET13G/A6.85%8.24M shares−1.75 ppfrom 8.60%Dec 31, 2025SEC
QUREuniQure N.V.Jan 29, 20263:15 PM ET13G/A5.91%3.68M shares+1.14 ppfrom 4.77%Dec 31, 2025SEC
TECXTectonic Therapeutic, Inc.Jan 29, 20263:15 PM ET13G6.10%1.14M sharesNewDec 31, 2025SEC